Garuda Therapeutics Announces the Appointment of Giorgia Scapin, Ph.D., as Chief Scientific Officer
12 Jul 2023
Cell TherapyExecutive Change
-Dr. Scapin to continue her leadership and advancement of Garuda’s platform technology for generating self-renewing blood stem cells-
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Garuda Therapeutics (Garuda), a company creating off-the-shelf, durable blood stem cell-based cellular therapies, today announced the appointment of Giorgia Scapin, Ph.D., as Chief Scientific Officer. Transitioning from her previous role as Senior Vice President of Research and Development at Garuda, Dr. Scapin will oversee the company’s scientific strategy and lead the advancement of Garuda’s off-the-shelf hematopoietic stem cell (HSC) therapies in her new role as Chief Scientific Officer.
“Dr. Scapin has played an instrumental role in the advancement of our platform technology since Garuda’s inception. As a co-inventor and a member of the Harvard laboratory that discovered the technology behind Garuda’s platform, Dr. Scapin has served as an instrumental leader, helping to lead the team that is advancing the development of our off-the-shelf durable blood stem cell and immune cell programs,” said Dhvanit Shah, Ph.D., Co-Founder and CEO of Garuda. “I am confident that under Dr. Scapin’s leadership as Chief Scientific Officer, Garuda has the potential to provide transformative treatments to patients with a broad range of severe and life-threatening diseases.”
“Garuda is poised to become a world leader in providing HSC-based cellular therapies to treat blood disorders. Dr. Scapin’s promotion to a Chief Scientific Officer position affirms her leadership, growth, and vision to advance Garuda’s goals, while demonstrating Garuda’s commitment to supporting highly driven leaders with illustrious international reputations in medicine,” said Eric Aguiar, M.D., a Board Director of Garuda.
Dr. Scapin is an expert in blood stem cell and bone marrow transplants, with a background in molecular biology and hematopoietic stem cell research. Prior to serving as the company’s Senior Vice President of Research and Development, Dr. Scapin conducted extensive research at Brigham and Women’s Hospital, Harvard Medical School, and the Harvard Stem Cell Institute-based laboratory that uncovered the technology underpinning Garuda’s science. Dr. Scapin received her Ph.D. in Bioscience and Biotechnology from the Università degli Studi di Padova, Italy.
“Garuda’s disruptive technology has the potential to revolutionize the hematopoietic stem cell transplant practice and bypass many of the challenges associated with existing treatments,” said Dr. Scapin. “It’s energizing to work alongside a team with the shared mission of advancing durable, cost-effective and scalable medicines, and I look forward to supporting Garuda as we work tirelessly to bring these transformative cellular therapeutics to patients everywhere.”
About Garuda Therapeutics
Garuda Therapeutics seeks to create a world that eliminates the dependency on donor or patient cells for blood stem cell transplants. Our platform technology for generating off-the-shelf, self-renewing blood stem cells is poised to provide patients with rapid and broad access to consistent, durable, HLA-compatible and transgene-free blood stem cell therapies. Like bone marrow transplants, our technology could provide potentially curative therapies for more than 120 diseases.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.